Automate Your Wheel Strategy on GMED
With Tiblio's Option Bot, you can configure your own wheel strategy including GMED - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GMED
- Rev/Share 18.3596
- Book/Share 29.8929
- PB 1.7941
- Debt/Equity 0.0226
- CurrentRatio 4.4453
- ROIC 0.0495
- MktCap 7260395452.0
- FreeCF/Share 3.7847
- PFCF 14.0274
- PE 39.5245
- Debt/Assets 0.0196
- DivYield 0
- ROE 0.0455
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GMED | BTIG Research | Buy | Neutral | -- | -- | May 27, 2025 |
| Upgrade | GMED | BofA Securities | Underperform | Neutral | -- | $97 | Jan. 10, 2025 |
News
International Growth Drives GMED Stock Amid Fierce Competition
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Read More
GMED Stock May Benefit Following the Acquisition of Nevro
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.
Read More
Globus Medical completes acquisition of Nevro Corp.
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain.
Read More
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
Published: March 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
Read More
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
Read More
New Product Launches Benefit GMED Stock Amid Macro Issues
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Read More
Globus Medical, Inc. (GMED) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Globus Medical, Inc. (NYSE:GMED ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Vik Chopra - Wells Fargo Matt Miksic - Barclays David Saxon - Needham & Company Jason Wittes - ROTH Shagun Singh - RBC Caitlin Cronin - Canaccord Genuity Craig Bijou - Bank of America Securities Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Ryan Zimmerman - BTIG Matthew Blackman - Stifel Operator Welcome to the Globus Medical's Fourth …
Read More
Globus Medical (GMED) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Globus Medical (GMED) Q4 Earnings and Revenues Top Estimates
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Globus Medical (GMED) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.60 per share a year ago.
Read More
Globus Medical: Q4 Revenue Tops Forecast
Published: February 20, 2025 by: The Motley Fool
Sentiment: Positive
Medical technologies specialist Globus Medical (GMED 0.04%) reported impressive results for the fourth quarter of 2024 on Thursday, Feb. 20. The highlights included adjusted earnings per share (EPS) of $0.84, exceeding the consensus forecast of $0.75, along with revenue that reached $657.3 million, topping expectations by $12.3 million.
Read More
About Globus Medical, Inc. (GMED)
- IPO Date 2012-08-03
- Website https://www.globusmedical.com
- Industry Medical - Devices
- CEO Daniel T. Scavilla
- Employees 5300